Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Prospective randomized study in order to compare intravenous versus subcutaneous
administration of amifostine in patients receiving radiotherapy for head and neck cancer.
Salivary flow will be evaluated during few years after the treatment by a clinical
evaluation, the measure of the weight of saliva and a patient benefit questionnaire cotation.